Lixisenatide: a review of its use in patients with type 2 diabetes mellitus (Q38126893)

29 August 2017

Lixisenatide: a review of its use in patients with type 2 diabetes mellitus (English)

1 reference

29 August 2017

1 reference

1

Lesley J Scott

1 reference

PubMed ID

23918699

29 August 2017

language of work or name

1 reference

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

27

1 reference

29 August 2017

509-523

1 reference

29 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0057-y

29 August 2017

0 references

cites work

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Year in diabetes 2012: The diabetes tsunami

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Unraveling the science of incretin biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Postprandial hyperglycemia as an etiological factor in vascular failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Intensive glucose control and macrovascular outcomes in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Systematic review: glucose control and cardiovascular disease in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Glycemic control and complications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Patient adherence to medication requirements for therapy of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0057-Y

10.1007/S40259-013-0057-Y

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23918699